TiumBio, Oral Immunotherapy Oncology Drug Confirmed Additional Partial Response in Phase 1b
Tium Bio CI (Health Korea News / Yu Ji-in) Tium Bio announced on the 26th that it had confirmed additional partial response (PR) patients in the phase 1b clinical trial of ‘TU2218’, an oral immune anticancer drug under development. This … Read more